Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Inherit Metab Dis ; 24(4): 427-36, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11596647

ABSTRACT

A feline model of Niemann-Pick disease type C (NPC) was employed to evaluate the effect of dietary cholesterol restriction on progression of disease. Two NPC-affected treated cats were fed a cholesterol-restricted diet beginning at 8 weeks of age; the cats remained on the diet for 150 and 270 days respectively. The study goal was to lower the amount of low density lipoprotein (LDL) available to cells, hypothetically reducing subsequent lysosomal accumulation of unesterified cholesterol and other lipids. Neurological progression of disease was not altered and dietary cholesterol restriction did not significantly decrease storage in NPC-affected treated cats. One NPC-affected treated cat had decreased serum alkaline phosphatase activity (ALP) and decreased serum cholesterol concentration. Liver lipid concentrations of unesterified cholesterol, cholesterol ester and phospholipids in NPC-affected treated cats were similar to those seen in NPC-affected untreated cats. Ganglioside concentrations in the NPC-affected treated cats and NPC-affected untreated cats were similar. Histological findings in liver sections from NPC-affected treated cats showed a diffuse uniform microvacuolar pattern within hepatocytes and Kupffer cells, in contrast to a heterogeneous macro/microvacuolar pattern and prominent nodular fibrosis in NPC-affected untreated cats. Similar differences in vacuolar patterns were seen in splenic macrophages. Although some hepatic parameters were modified, dietary cholesterol restriction did not appear to alter disease progression in NPC-affected kittens.


Subject(s)
Cholesterol, Dietary/administration & dosage , Disease Models, Animal , Niemann-Pick Diseases/diet therapy , Alanine Transaminase/blood , Alkaline Phosphatase/blood , Animals , Bilirubin/blood , Cats , Cholesterol/blood , Cytoplasm/ultrastructure , Lipids/analysis , Liver/chemistry , Liver/ultrastructure , Niemann-Pick Diseases/pathology , Niemann-Pick Diseases/physiopathology , Serum Albumin/analysis , Vacuoles/pathology
2.
Curr Biol ; 11(16): 1283-7, 2001 Aug 21.
Article in English | MEDLINE | ID: mdl-11525744

ABSTRACT

Niemann-Pick type C (NPC) disease is a cholesterol lipidosis caused by mutations in NPC1 and NPC2 gene loci. Most human cases are caused by defects in NPC1, as are the spontaneously occurring NPC diseases in mice and cats. NPC1 protein possesses a sterol-sensing domain and has been localized to vesicles that are believed to facilitate the recycling of unesterified cholesterol from late endosomes/lysosomes to the ER and Golgi. In addition to accumulating cholesterol, NPC1-deficient cells also accumulate gangliosides and other glycosphingolipids (GSLs), and neuropathological abnormalities in NPC disease closely resemble those seen in primary gangliosidoses. These findings led us to hypothesize that NPC1 may also function in GSL homeostasis. To evaluate this possibility, we treated murine and feline NPC models with N-butyldeoxynojirimycin (NB-DNJ), an inhibitor of glucosylceramide synthase, a pivotal enzyme in the early GSL synthetic pathway. Treated animals showed delayed onset of neurological dysfunction, increased average life span (in mice), and reduced ganglioside accumulation and accompanying neuropathological changes. These results are consistent with our hypothesis and with GSLs being centrally involved in the pathogenesis of NPC disease, and they suggest that drugs inhibiting GSL synthesis could have a similar ameliorating effect on the human disorder.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , 1-Deoxynojirimycin/therapeutic use , Carrier Proteins/metabolism , Glycosphingolipids/metabolism , Membrane Glycoproteins/metabolism , Niemann-Pick Diseases/drug therapy , Niemann-Pick Diseases/metabolism , Age Factors , Animals , Carrier Proteins/genetics , Cats , Cerebellum/cytology , Cerebellum/drug effects , Disease Models, Animal , Enzyme Inhibitors/therapeutic use , Glycoside Hydrolase Inhibitors , Humans , Immunohistochemistry , Intracellular Signaling Peptides and Proteins , Membrane Glycoproteins/genetics , Mice , Niemann-Pick C1 Protein
3.
Mol Genet Metab ; 66(2): 117-21, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10068514

ABSTRACT

Complementation studies were performed to determine if the gene responsible for the major form of human Niemann-Pick type C disease (NPC) and a feline model of NPC are orthologous. Cell fusions between human NPC and feline NPC fibroblasts were conducted to assess whether the multinucleated heterokaryons that were formed showed a reversal of the NPC phenotype. Cultured fibroblasts from NPC-affected humans and NPC-affected cats were hybridized and then analyzed for complementation by challenging the cells with low-density lipoprotein (LDL) and subsequently staining with the fluorescent antibiotic filipin to visualize any abnormal accumulation of unesterified cholesterol. All of the multinucleated cells formed from these fusions retained the NPC staining phenotype, indicating an absence of complementation and suggesting that the underlying defect in the major form of human NPC and this feline model of NPC involve orthologous genes.


Subject(s)
Cat Diseases/genetics , Genetic Complementation Test , Niemann-Pick Diseases/genetics , Niemann-Pick Diseases/veterinary , Animals , Cats , Cell Fusion , Cell Line , Cell Nucleus/pathology , Fibroblasts/pathology , Humans , Phenotype
SELECTION OF CITATIONS
SEARCH DETAIL
...